Mitchell E. Gross

4.5k total citations
122 papers, 3.5k citations indexed

About

Mitchell E. Gross is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Mitchell E. Gross has authored 122 papers receiving a total of 3.5k indexed citations (citations by other indexed papers that have themselves been cited), including 71 papers in Pulmonary and Respiratory Medicine, 41 papers in Oncology and 27 papers in Molecular Biology. Recurrent topics in Mitchell E. Gross's work include Prostate Cancer Treatment and Research (57 papers), Prostate Cancer Diagnosis and Treatment (13 papers) and Cancer Genomics and Diagnostics (12 papers). Mitchell E. Gross is often cited by papers focused on Prostate Cancer Treatment and Research (57 papers), Prostate Cancer Diagnosis and Treatment (13 papers) and Cancer Genomics and Diagnostics (12 papers). Mitchell E. Gross collaborates with scholars based in United States, Canada and France. Mitchell E. Gross's co-authors include David B. Agus, Ke Shuai, Tanya B. Dorff, George Wilding, Inderbir S. Gill, Osamu Ukimura, Andre Luis Abreu, Bin Liu, Johanna ten Hoeve and Maha Hussain and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and ACS Nano.

In The Last Decade

Mitchell E. Gross

119 papers receiving 3.4k citations

Peers

Countries citing papers authored by Mitchell E. Gross

Since Specialization

Citations

This map shows the geographic impact of Mitchell E. Gross's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mitchell E. Gross with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mitchell E. Gross more than expected).

Fields of papers citing papers by Mitchell E. Gross

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mitchell E. Gross. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mitchell E. Gross. The network helps show where Mitchell E. Gross may publish in the future.

Co-authorship network of co-authors of Mitchell E. Gross

This figure shows the co-authorship network connecting the top 25 collaborators of Mitchell E. Gross. A scholar is included among the top collaborators of Mitchell E. Gross based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mitchell E. Gross. Mitchell E. Gross is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	In Vivo Non-Thermal, Selective Cancer Treatment With High-Frequency Medium-Intensity Focused Ultrasound 2021 ·IEEE Access ·(unknown), (unknown), Ailin Zhang, Chun‐Peng Liao, Mitchell E. Gross, Eun Sok Kim	4
2	Phase 2 trial of monoamine oxidase inhibitor phenelzine in biochemical recurrent prostate cancer 2020 ·Prostate Cancer and Prostatic Diseases ·Mitchell E. Gross, David B. Agus, Tanya B. Dorff, Jacek Pinski, David I. Quinn, (unknown), (unknown), Jean C. Shih	42
3	CCR2-targeted micelles for anti-cancer peptide delivery and immune stimulation 2020 ·Journal of Controlled Release ·(unknown), (unknown), Ailin Zhang, Chun‐Peng Liao, Christopher Poon, Jonathan Wang, (unknown), (unknown), Carolina Garri, K. Robert Shen, Kian Kani, Mitchell E. Gross, Eun Ji Chung	33
4	Effect of Monoamine oxidase A (MAOA) inhibitors on androgen‐sensitive and castration‐resistant prostate cancer cells 2019 ·The Prostate ·Shikha Gaur, Mitchell E. Gross, Chun‐Peng Liao, Bin Qian, Jean C. Shih	47
5	Monitoring dynamic cytotoxic chemotherapy response in castration-resistant prostate cancer using plasma cell-free DNA (cfDNA) 2019 ·BMC Research Notes ·(unknown), Naim Matasci, (unknown), (unknown), David B. Agus, Daniel Ruderman, Mitchell E. Gross	21
6	Loss of ER retention motif of AGR2 can impact mTORC signaling and promote cancer metastasis 2018 ·Oncogene ·Katrin Tiemann, Carolina Garri, Sang Bok Lee, Paymaneh D. Malihi, Min-Cheol Park, (unknown), (unknown), Parag Mallick, Jonathan E. Katz, Mitchell E. Gross, Kian Kani	28
7	Genomic alterations in plasma DNA from patients with metastasized prostate cancer receiving abiraterone or enzalutamide 2018 ·International Journal of Cancer ·Jelena Belic, Ricarda Graf, Thomas Bauernhofer, (unknown), Peter Ulz, Julie Waldispuehl‐Geigl, Samantha Perakis, Michael Gormley, Jaymala Patel, Weimin Li, Jochen B. Geigl, Denis A. Smirnov, Ellen Heitzer, Mitchell E. Gross, Michael R. Speicher	40
8	A pilot randomised controlled trial of a periodised resistance training and protein supplementation intervention in prostate cancer survivors on androgen deprivation therapy 2017 ·BMJ Open ·(unknown), Tanya B. Dorff, E. Todd Schroeder, George J. Salem, Christianne J. Lane, Judd C. Rice, Mitchell E. Gross, Christina M. Dieli‐Conwright	13
9	Protein Mimetic and Anticancer Properties of Monocyte-Targeting Peptide Amphiphile Micelles 2017 ·ACS Biomaterials Science & Engineering ·Christopher Poon, (unknown), Cheng‐Hsiang Kuo, Yun Fang, Francis J. Alenghat, (unknown), Kian Kani, Mitchell E. Gross, Eun Ji Chung	28
10	Phase I/II Trial of Orteronel (TAK-700)—an Investigational 17,20-Lyase Inhibitor—in Patients with Metastatic Castration-Resistant Prostate Cancer 2014 ·Clinical Cancer Research ·Robert Dreicer, David B. MacLean, Ajit Suri, Walter M. Stadler, Daniel H. Shevrin, Lowell L. Hart, Gary R. MacVicar, Omid Hamid, John D. Hainsworth, Mitchell E. Gross, (unknown), Iain J. Webb, David B. Agus	34
11	Quantitative Proteomic Profiling Identifies Protein Correlates to EGFR Kinase Inhibition 2012 ·Molecular Cancer Therapeutics ·Kian Kani, Vítor M. Faça, Lindsey D. Hughes, Wenxuan Zhang, Qiaojun Fang, Babak Shahbaba, Roland Luethy, Jonathan Erde, (unknown), Sharon J. Pitteri, Qing Zhang, Jonathan E. Katz, Mitchell E. Gross, Sylvia K. Plevritis, Martin McIntosh, Anjali Jain, Samir Hanash, David B. Agus, Parag Mallick	6
12	Cytometric comparisons between circulating tumor cells from prostate cancer patients and the prostate-tumor-derived LNCaP cell line 2012 ·Physical Biology ·Daniel C. Lazar, Edward H. Cho, Madelyn Luttgen, Thomas J. Metzner, Maria Uson, (unknown), Mitchell E. Gross, Peter Kühn	53
13	Prospective Evaluation of 18F-NaF and 18F-FDG PET/CT in Detection of Occult Metastatic Disease in Biochemical Recurrence of Prostate Cancer 2012 ·Clinical Nuclear Medicine ·Hossein Jadvar, Bhushan Desai, Lingyun Ji, Peter S. Conti, Tanya B. Dorff, Susan Groshen, Mitchell E. Gross, Jacek Pinski, David I. Quinn	100
14	A Phase I, open-label, dose-escalation study of continuous once-daily oral treatment with afatinib in patients with advanced solid tumors 2012 ·Investigational New Drugs ·Michael S. Gordon, David S. Mendelson, Mitchell E. Gross, Martina Uttenreuther‐Fischer, Mahmoud Ould-Kaci, Yihua Zhao, Peter Stopfer, David B. Agus	31
15	Safety and pharmacokinetics of high-dose gefitinib in patients with solid tumors: results of a phase I study 2011 ·Cancer Chemotherapy and Pharmacology ·Mitchell E. Gross, Lawrence Leichman, Elizabeth Lowe, Alan Swaisland, David B. Agus	11
16	CELL LYSIS BY LOW POWER FOCUSED ACOUSTIC TRANSDUCER AND INVESTIGATION OF ACOUSTIC INTENSITY THRESHOLD FOR CYTOLYSIS OF VARIOUS CELL LINES 2011 ·Lingtao Wang, Yijia Li, (unknown), (unknown), Mitchell E. Gross, Eun Sok Kim	0
17	Predictors of affect following treatment decision‐making for prostate cancer: conversations, cognitive processing, and coping 2008 ·Psycho-Oncology ·(unknown), Beth E. Meyerowitz, (unknown), Mitchell E. Gross, David B. Agus	39
18	Raloxifene, an oestrogen‐receptor‐β‐targeted therapy, inhibits androgen‐independent prostate cancer growth: results from preclinical studies and a pilot phase II clinical trial 2005 ·British Journal of Urology ·Ronald Shazer, Anjali Jain, Anna Galkin, Nadya M. Cinman, (unknown), Ronald B. Natale, Mitchell E. Gross, (unknown), (unknown), Stuart Holden, (unknown), David B. Agus	37
19	Protein partners of C/EBPε 2004 ·Experimental Hematology ·Doris Y. Chih, Dorothy J. Park, Mitchell E. Gross, Gregory Idos, Peter T. Vuong, Toshiyasu Hirama, Alexey M. Chumakov, Jonathan Said, H. Phillip Koeffler	19
20	Preliminary observations of protistan organisms, especially ciliates, from the 21°N hydrothermal vent site 1985 ·E. B. Small, Mitchell E. Gross	22

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact